Breast Fat Grafting After Cancer / Lipomodelling | Healing, lumps and imaging

Pressure and shear can disturb newly transferred fat before it gains blood supply, so minimizing forces on the breast supports engraftment. A surgical bra is worn day and night, and sleeping on the stomach is avoided for one month. Donor sites are usually protected with compressive dressings to reduce seroma or hematoma risk. Because resorption is unpredictable, multiple rounds may be needed to reach the desired volume; surgeons often undercorrect and plan possible touch-up sessions. Tissue quality may improve after initial grafting. For cancer reconstruction, fat grafting is generally considered only when the local breast is free of disease, with careful postoperative imaging and multidisciplinary follow-up.

Fat grafts need a calm recipient site. Pressure over the grafted breast can reduce fat viability, so compression is avoided there and a low-pressure supportive bra is used instead. Compression over donor sites helps limit bruising and supports drainage of tumescent fluid after liposuction. General liposuction guidance describes wearing the garment for the first month, around the clock for the first two weeks, then at night for two weeks. Only patients free of local breast disease are considered eligible, with appropriate clinical and radiological breast evaluation. Fat grafting may require several sessions, especially after radiation. Your surgeon will individualize garment timing, breast support, donor-site recovery, and comfort based on healing as needed.

Fat grafting after breast cancer treatment and reconstruction is used to correct contour deformities and step-offs, often at the breast periphery, and may require several sessions. Successful grafting depends on recipient-site compliance and capacity, plus careful harvesting, processing and delivery. Graft survival varies with harvest, processing and delivery methods, and recipient-site vascularity. Fat resorption is frequently quoted at 30% to 70% within a year, with most volume change in the first three months and possible change up to six months. If a contour deformity remains after swelling resolves, waiting at least six months before another round is recommended. There are no changes in routine postoperative mammography or breast oncology follow-up.

This MRI-based method assumes the measured breast-volume change reflects grafted fat, but swelling, tissue changes and measurement error can affect the result. The typical procedure measures total breast volume before and after surgery when no further resorption is expected, subtracts preoperative volume, and divides by injected volume. In studies of fat transfer with added stem-cell-rich tissue, MRI before surgery and at three and six months afterward was used to calculate resorption. Because fat grafting often needs more than one session and results vary, your surgeon interprets imaging alongside examination rather than relying on one number. This is a research-style estimate, not a personal guarantee of how much fat will survive in your breast.

Fat grafting moves harvested fat to correct contour defects after breast cancer treatment; some transferred fat may not survive if the recipient area has limited blood supply. The resulting fat necrosis can create lumps, oil cysts, calcifications, firmness, or contour irregularity. It can present as a palpable nodule that may be mistaken for malignancy, though calcifications after grafting usually look benign and can often be distinguished from cancer-related changes; if findings are indeterminate, biopsy may be recommended. These changes are usually benign and may resolve or be managed conservatively, but in breast cancer patients a new lump can be hard to distinguish from recurrence, so imaging and sometimes needle biopsy are used when findings are uncertain.

Fat necrosis, oil cysts and calcifications can occur when large volumes are injected into one area or fat is placed in poorly vascularized tissue, so graft take fails. These changes may feel like a lump and can be hard to distinguish from recurrence; additional imaging or needle biopsy may then be needed. Calcifications after fat grafting may be coarse or fine microcalcifications and are usually distinguishable from suspicious cancer-related patterns by an experienced radiologist. Subcutaneous fat grafting does not interfere with breast examination or cancer follow-up, and most abnormalities are benign. Only doubtful cases need further tests. Careful technique reduces but does not eliminate this risk.

Fat necrosis and oil cysts can form when grafted fat does not survive, sometimes after large-volume or poorly placed injection. On imaging, cancer recurrence more often appears as an irregular mass with pleomorphic calcifications and rapid contrast uptake, while fat necrosis or oil cysts tend to show coarse calcifications with no or gradual contrast uptake. An experienced radiologist can usually tell these patterns apart. Fat grafting in the subcutaneous layer does not interfere with breast examination or oncologic follow-up; ultrasound, MRI or fine-needle biopsy help when doubt remains. Calcifications from fat necrosis are substantially different from those induced by breast cancer. Earlier imaging may provide a useful comparison if later changes appear.

Fat grafting can leave expected benign changes, so the goal is to identify suspicious lesions early while avoiding unnecessary biopsies for expected postoperative findings. Mammography is favored for differentiating cancer from benign breast lesions and identifying microcalcifications; ultrasound and MRI can image questionable lesions. If there is clinical suspicion or an indeterminate radiologic abnormality, biopsy should always be considered. Patients with prior cancer need careful follow-up, and pre-grafting imaging provides a comparison baseline. Only patients free of local breast disease are considered eligible, and appropriate clinical and radiological evaluation is required before grafting. Regular physician exams and annual mammograms are also advised.

Fat grafting can leave expected benign breast changes, so the aim is to distinguish them from recurrence. One source recommends mammography, ultrasound and MRI before the first grafting session to rule out recurrence and create a comparison baseline; by three months after the first session, repeat imaging may add little. For patients with cancer history, mammography before grafting and annual or more frequent follow-up is advised, with frequency depending on findings. After the last session, one first-year schedule includes ultrasound and MRI at three, six and twelve months and mammography at twelve months. Mammography is especially useful for microcalcifications, but it is not enough alone; concerning findings may need extra imaging or biopsy.

Expected discomfort is usually moderate, and patients rarely have significant breast pain, although donor sites such as the back or sacrum can be quite painful. Infection may develop if a haematoma, fat necrosis or oil cyst occurs, because non-vascularised grafted fat can become a substrate for infection. Perioperative antibiotics are not routinely used unless there is a specific clinical indication, although intraoperative antibiotics are recommended. Delayed infections or infections not responding rapidly to routine antibiotics should raise suspicion of atypical or nontuberculous mycobacterial infection; signs can range from cellulitis and draining sinuses to abscess or chronic granuloma formation, with variable systemic signs and usually non-purulent, light yellow serous discharge.